Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vistin Pharma ASA ( (DE:VP4) ) has issued an update.
Vistin Pharma ASA reported a revenue increase in the third quarter of 2025, driven by a 10% rise in sales volume, although EBITDA was slightly lower due to reduced global metformin prices. The company achieved a record production volume of 1,600MT of metformin, indicating strong operational performance and potential positive implications for stakeholders.
More about Vistin Pharma ASA
Vistin Pharma ASA is a pharmaceutical company based in Oslo, Norway, primarily engaged in the production of metformin, a medication used to treat type 2 diabetes. The company focuses on increasing production volumes and expanding its market presence in the global pharmaceutical industry.
Average Trading Volume: 18,982
Current Market Cap: NOK980M
See more insights into VP4 stock on TipRanks’ Stock Analysis page.